heres how much $1000 invested in amgen 15 years ago would be worth today. amgen (nasdaq:) has outperformed the market over the past 15 years by 3.48% on an annualized basis producing an average annual return of 11.44%. currently amgen has a market capital

amgen sees potential for horizon to close by mid-december under court schedule.

amgen (amgn) shares cross 4% yield mark. looking at the universe of stocks we cover at dividend channel in trading on thursday shares of amgen inc (symbol: amgn) were yielding above the 4% mark based on its quarterly dividend (annualized to

notable thursday option activity: amgn abbv rcl. looking at options trading activity among components of the s&.p 500 index there is noteworthy activity today in amgen inc (symbol: amgn) where a total volume of 19544 contracts has been tr

amgen: now at a record high yield.

noteworthy wednesday option activity: amgn gpre reta. looking at options trading activity among components of the russell 3000 index there is noteworthy activity today in amgen inc (symbol: amgn) where a total volume of 14209 contracts has b

us judge hearing fight over amgen deal for horizon eyes september trial. the judge who will decide if amgen can go forward with its $27.8 billion purchase of horizon therapeutics on tuesday said he was considering an evidentiary hearing on the m

dow movers: wba amgn. in early trading on monday shares of amgen topped the list of the days best performing dow jones industrial average components trading up 1.2%. year to date amgen has lost about 13.9% of its value.

ideaya announces fda nod to run amgen-sponsored tumor study.

oppenheimer reiterates amgen (amgn) outperform recommendation. fintel reports that on may 18 2023 oppenheimer reiterated coverage of amgen (nasdaq:amgn) with a outperform recommendation. analyst price forecast suggests 16.17% upside

amgen agrees not to seek quick close to horizon acquisition. amgen inc has agreed not to quickly close on its $27.8 billion acquisition of horizon therapeutics after the United States federal trade commission (ftc) filed suit to block the deal.

amgen agrees not to close horizon deal before sept. 15 in court agreement with ftc.

United States court issues temporary restraining order on $27.8 bln amgen-horizon deal. a United States district court has issued a temporary restraining order on amgen incs $27.8 billion acquisition of horizon therapeutics following a submissio

ftc effort to stop amgens horizon takeover faces uphill fight.

unusual put option trade in amgen (amgn) worth $6563.75k. on may 17 2023 at 11:26:46 et an unusually large $6563.75k block of put contracts in amgen (amgn) was sold with a strike price of $245.00 / share expiring in 65 day(s) (on july 21 2023)

unusual put option trade in amgen (amgn) worth $9481.50k. on may 17 2023 at 14:36:36 et an unusually large $9481.50k block of put contracts in amgen (amgn) was bought with a strike price of $250.00 / share expiring in 30 day(s) (on june 16 202

ftc challenges amgens (amgn) $28b acquisition of horizon. on tuesday the federal trade commission (&ldquo.ftc&rdquo.) filed a lawsuit in federal court to halt biotech giant amgens amgn $28 billion acquisition of horizon therapeutics hz

noteworthy wednesday option activity: amgn lkq lyv. looking at options trading activity among components of the s&.p 500 index there is noteworthy activity today in amgen inc (symbol: amgn) where a total volume of 32927 contracts has been

amgen deal for horizon likely to go through despite ftc objection: guggenheim.

amgen becomes oversold. the dividendrank formula at dividend channel ranks a coverage universe of thousands of dividend stocks according to a proprietary formula designed to identify those stocks that combine two important characteristics &m

ftc may reportedly block amgens (amgn) $28b horizon buyout. shares of horizon therapeutics hznp were down 15% in after-market trading on may 15 after multiple third-party articles stated that the federal trade commission (&ldquo.ftc&rd

United States sues to block amgens $27.8 billion takeover of horizon therapeutics. the federal trade commission said the deal would enable amgen to entrench the monopoly positions of two horizon drugs that lack competition.

ftc moves to block amgens $27.8 billion deal for horizon therapeutics. the ftc filed a lawsuit in federal court seeking an injunction that would prevent the deal from closing.

horizon therapeutics falls on ftcs reported move to challenge amgens $28 bln deal. (rttnews) - horizon therapeutics public ltd co. (hznp) shares are sliding more than 17 percent on tuesday morning trade after the United States federal trade comm

ftc poised to block amgens $27.8 billion deal for horizon therapeutics. the ftc is preparing to seek an injunction in federal court that would prevent the deal from closing.

amgen-horizon therapeutics deal regulatory overhang: ftc plans lawsuit to block $28b takeover. the federal trade commission is expected to file a lawsuit in a bid to block) $28 billion takeover of). in december amgen agreed to buy horizon therapeutics at

ftc to block amgens deal to buy horizon - bloomberg news. the us federal trade commission (ftc) is expected to file a lawsuit on tuesday to block amgen incs $27.8 billion deal to buy horizon therapeutics plc citing risks to competition in drug d

ftc to block amgens deal to acquire horizon - source. the us federal trade commission (ftc) is expected to file a lawsuit as early as tuesday to block amgen incs deal to buy horizon therapeutics plc a person familiar with the matter told reuters

ex-dividend reminder: amgen select medical holdings and laboratory corporation of america holdings. looking at the universe of stocks we cover at dividend channel on 5/17/23 amgen inc (symbol: amgn) select medical holdings corp (symbol: sem)

tscan jumps 102% after deal with amgen for crohns disease.